Alyeska Investment Group, L.P. Trevi Therapeutics, Inc. Transaction History
Alyeska Investment Group, L.P.
- $25.4 Billion
- Q2 2025
A detailed history of Alyeska Investment Group, L.P. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 650,000 shares of TRVI stock, worth $6.87 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
650,000Holding current value
$6.87 Million% of portfolio
0.01%Shares
4 transactions
Others Institutions Holding TRVI
# of Institutions
163Shares Held
110MCall Options Held
1.07MPut Options Held
425K-
Nea Management Company, LLC Timonium, MD13.2MShares$140 Million6.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$108 Million2.96% of portfolio
-
Rubric Capital Management LP New York, NY8.53MShares$90.2 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.32MShares$56.2 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.49MShares$47.4 Million5.2% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $616M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...